SLDB Q3 2022 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$581M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$21M

Net Income

-$20M

EPS (Diluted)

$-2.71

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$184M

Total Liabilities

$41M

Stockholders' Equity

$143M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$4M	-100.0%
Gross Profit	$0	$4M	-100.0%
Operating Income	-$21M	-$18M	-17.2%
Net Income	-$20M	-$18M	-13.5%